|

Palbociclib 125mg Clinical Trials

7 actively recruiting trials across 3 locations

Also known as: Ibrance, anti-CDK4/6

Other4 trials

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Phase 1/2
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
Phase 1
PLATFORM Study of Precision Medicine for Rare Tumors
Phase 2
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Phase 1

Chandler, Arizona1 trial

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Ironwood Cancer & Research Centers

Phase 3

Tucson, Arizona1 trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

The University of Arizona Cancer Center

Phase 1

New York, New York1 trial

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Weill Cornell Medicine

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.